Immunome, Inc. (IMNM)
|Net Income (ttm)||-11.05M|
|Trading Day||January 25|
|Day's Range||14.71 - 17.95|
|52-Week Range||9.46 - 17.95|
Immunome Provides Organizational Update: Appoints Richard Baron to its Board of Directors and Sandra Stoneman as Chief Legal Officer and Corporate Secretary
EXTON, Pa.--(BUSINESS WIRE)--Immunome appoints Richard Baron to BOD and Sandra Stoneman as Chief Legal Officer and Corporate Secretary
EXTON, Pa.--(BUSINESS WIRE)--Immunome Reports Third Quarter 2020 Financial Results and Significant Progress
EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody the...
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider b...
EXTON, Pa.--(BUSINESS WIRE)--Immunome Announces Pricing of Upsized Initial Public Offering
Immunome Aims For $30 Million U.S. IPO
Immunome Inc. set terms for its initial public offering, in which the Pennsylvania-based biopharmaceutical company focused on oncology looks to raise up to $32.5 million. The company is offeri...
Immunome, a biotechnology company, discovers, develops, and commercializes highly targeted and native human cancer antibodies against universal cancer antigens. Its RealMAb technology enables the discovery of novel antigens and the cognate native human antibodies that target antigens; and ScreenMab multiplex functional screening technology identifies monoclonal antibodies that have exquisite for tumor neoantigens. The company was founded in 2006 and is based in Exton, Pennsylvania.
|IPO Date |
Oct 2, 2020
Dr. Purnanand Duddu Sarma
|Stock Exchange |
|Ticker Symbol |
According to 2 analysts, the average rating for Immunome stock is "Strong Buy." The 12-month stock price forecast is 23.00, which is an increase of 28.85% from the latest price.